Conditioning regimens with reduced intensity are used increasingly for allogeneic stem cell transplantation in elderly or extensively pretreated patients. Two cases of pure red cell aplasia after fludarabine-based conditioning and during immunosuppression with cyclosporin are described. Both patients received AB0-mismatched stem cells and had anti-donor isoagglutinins. Red cell recovery occurred after extended immunosuppression when isoagglutinins had disappeared. Colony assays indicated serologic suppression of the erythrocyte lineage in one patient. Since reduced conditioning permits donor cell engraftment primarily by suppression of host T cells, antibody-mediated immunological complications may occur more frequently than after 'classical' conditioning. Bone Marrow Transplantation (2000) 26, 911-915. Keywords: red cell aplasia; reduced conditioning; isoagglutinins; fludarabine Reduced-intensity conditioning regimens extend the option of allogeneic stem cell transplantation to elderly or extensively pretreated patients.
Reduced-intensity conditioning regimens extend the option of allogeneic stem cell transplantation to elderly or extensively pretreated patients. 1, 2 The primary treatment goal of reduced conditioning is donor stem cell engraftment. After establishment of stable hematopoietic chimerism, the graftversus-malignancy effect may subsequently lead to eradication of tumor cells. 3 Donor cell engraftment depends on sufficient suppression of the recipient's T cells. Since fludarabine exerts a prominent and long-lasting immunosuppressive effect on T cells, 4 it has become a central agent in various reduced conditioning protocols. 2, 5 However, the immunological sequelae of reduced conditioning regimens are currently not well known. We describe two cases of pure red cell aplasia (PRCA) after allogeneic peripheral blood stem cell transplantation (PBSCT) across major AB0 barriers with the fludarabine-based FBM regimen. The mechanism of pure red cell aplasia is most likely explained by insufficient suppression of the recipient's isoagglutininsecreting B cells.
Patients and methods

Treatment protocol
The FBM regimen consists of fludarabine 30 mg/m 2 /day, days −9 to −5; BCNU 150 mg/m 2 /day, days −7 to −6; melphalan 110 mg/m 2 , day −4.
6 GVHD prophylaxis was performed with cyclosporin A (CsA, target serum level 250-350 g/l), and 5 mg/m 2 methotrexate intravenously on days +1, +3, and +6. Granulocyte recovery was supported by administration of filgrastim 300 g/day starting day +7 until granulocytes exceeded 1 × 10 9 /l.
Patient 1
A 53 year-old female was diagnosed with a myelodysplastic syndrome, subtype RA-RS, 69 months prior to PBSCT. The bone marrow karyotype was 46,XX,del(5)(q13q33), del(11)(q14). After progression to RAEB-T (22% bone marrow blasts), the patient underwent unselected PBSCT (6 × 10 6 /kg CD34 + cells) from her HLA-identical brother after FBM conditioning. Leukocyte (Ͼ1 × 10 9 /l) and thrombocyte engraftment (Ͼ20 × 10 9 /l) occurred on days +11 and +13, respectively. Cutaneous GVHD grade I developed on day +12 and resolved upon treatment with 0.3 mg/kg prednisone. However, her reticulocyte counts failed to recover, and she remained dependent on erythrocyte transfusions (Figure 1 ). Bone marrow biopsies showed complete remission (CR) with satisfactory megakaryopoiesis and granulopoiesis, but a subtotal to total absence of erythroid precursors on days +28, +71, and +175.
Patient 2
A follicular lymphoma, grade I, with involvement of left inguinal lymph nodes and suspected bone marrow involvement was diagnosed in patient 2 at the age of 41 years. After extended-field radiotherapy with 40 Gy, she was in CR for 11 months, when CT scans demonstrated enlarged iliac and retroperitoneal lymph nodes. Ten months later, progression of these lymphomas prompted treatment with 6 weeks of VACOP-B chemotherapy. Since no clinical response could be documented, she received one cycle of fludarabine, followed by FBM conditioning and unselected PBSCT (6.3 × 10 6 CD34 + /kg) from her HLA-identical sister. Leukocyte and thrombocyte engraftment occurred on days +10 and +13 of an uneventful post-transplant period. Cutaneous GVHD grade I was treated successfully with prednisone. The patient remained transfusion-dependent with inadequate reticulocyte counts. Three iliac crest biopsies showed total absence of the erythroid lineage in an otherwise well-repopulated bone marrow without lymphomatous infiltration ( Figure 2 ). Restaging with CT scans on day +98 demonstrated a very good partial remission of the abdominal masses.
Colony assay
Mononuclear cells were isolated from bone marrow aspirate by density gradient centrifugation. 1.5 × 10 5 cells were plated per ml in 3 ml semisolid IMDM methylcellulose medium supplemented with 30% fetal calf serum or patient serum. 20 ng/ml GM-CSF (Novartis, Nürnberg, Germany), 20 U/ml erythropoietin, or 400 ng/ml IL-3 (both from Cellgenix, Freiburg, Germany) were added as specific growth factors. CD3-and CD56-positive cells were depleted by monoclonal antibodies and magnetic beads (MACS system; Miltenyi Biotech, Auburn, CA, USA). Colonies were counted on day 14 after plating.
Molecular analysis of chimerism
The highly polymorphic variable nucleotide tandem repeat (VNTR) markers D1S80 and Tho 1 were amplified by PCR from genomic DNA and proved informative for both patient/donor pairs. As described in detail elsewhere, 6 PCR products were analyzed by polyacrylamide gel electrophoresis and silver staining to visualize specific bands. For the analysis of specific cellular subpopulations, CD3-, CD14-, and CD56-positive cells were separated from mononuclear cells with specific monoclonal antibodies coupled to microbeads (Miltenyi Biotech). In patient 1, chimerism was also assessed by interphase FISH for XY chromosomes (Vysis CEP XY Kit; Vysis, Stuttgart, Germany) according to the manufacturer's protocol. Four hundred interphase nuclei were analyzed (sensitivity 99.4%). Mixed chimerism (MC) was defined as у1% of recipient derived cells or DNA.
Results
Both patients had been transplanted across a major AB0 blood group barrier (patient 1: recipient 0 Rh+, donor A Rh+; patient 2: recipient 0 Rh−, donor A Rh−) in the presence of elevated anti-A isoagglutinin titers (Figures 1 and  2) . No clinically overt hemolysis could be documented. Tests for direct antiglobulin were negative in both patients (not shown). In 21 additional patients transplanted with the FBM regimen and GVHD prophylaxis with CsA and methotrexate, reticulocyte counts had recovered by day 54 (Table 1) . One patient (UPN 403) who suffered from acute myeloid leukemia Fab M7 with massive myelofibrosis which had developed secondary to essential thrombocytosis died from infectious complications prior to any sign of engraftment including granulocytes and thrombocyte recovery.
In patient 1, complete donor chimerism (CC) was dem- Patient 403 suffered from severe osteomyelofibrosis with secondary AML and died prior to engraftment. The immediate cause of death was infectious complications. UPN = unique patient no; n/a = not applicable; n/av = data not available. 
− cells at seven time-points between day +15 and + 112. In patient 2, PCR-based analyses of the informative marker D1S80 demonstrated a mixed chimerism of PBMC on day +5. Six independent analyses between day +12 and day +217 showed CC in the same subpopulations of cells that were examined in patient 1. In both patients, the percentage of B cells was too low to be analyzed reliably (Table 2) .
Colony assays with post-transplant bone marrow from patient 2 (insufficient material was available from patient 1) showed prominent suppression of BFU-E by autologous serum taken during pure red cell aplasia. BFU-E from blood group 0 bone marrow were not inhibited ( Table 3) . Depletion of T and natural killer cells did not influence colony growth. Therefore, outgrowth of erythoid precursor cells from transplanted stem cells was suppressed serologically. This effect persisted despite very low numbers of B cells and moderate to profound suppression of T lymphocyte subsets in the peripheral blood (Table 3) .
No other causes for PRCA could be identified. Despite presence of anti-parvovirus B19 IgG prior to transplantation in both patients, parvovirus B19 RNA was detected by PCR only once (day +175) in the bone marrow of patient 1, but not in patient 2. A T cell or NK cell- Mononuclear bone marrow cells of patient 2 taken on day +175 were plated at 1.5 × 10 5 cells per ml in 3 ml standard semisolid methyl cellulose RPMI medium supplemented with serum and GM-CSF, Epo, or IL-3 as indicated. Colonies were counted on day 14 after plating. CD3-and CD56-positive cells were depleted with monoclonal antibodies and magnetic beads. Bone marrow cells from a volunteer donor (blood group 0 Rh+) served as control cells. mediated aplastic anemia 7 is not supported by the observed pattern of colony growth. The endogeneous erythropoietin level was markedly elevated (Ͼ300 IU/l) in both patients during PRCA.
Addition of prednisone (0.8 to 1 mg/kg/day) to the routine immunosuppression with CsA failed in both cases to improve reticulocyte counts (Figures 1 and 2 ). Treatment of patient 1 with immunoglobulin, erythropoietin (up to 8000 U three days per week), and daily plasmaphereses had only marginal effects on reticulocyte counts. A sudden rise in reticulocyte counts and cessation of transfusion requirements occurred in both patients more than 6 months after PBSCT and 8 to 10 weeks after addition of mycophenolate mofetil (MMF) to the immunosuppressive regimen (patient 1, 2 × 0.5 g per day; patient 2, 2 × 1 g per day). At this time, anti-A titers had fallen to 1:8 and undetectable values, respectively, and an additional dose of intravenous immunoglobulin had been given. The red cell parameters remained stable under eventual reduction of immunosuppression.
Discussion
Immunologically mediated PRCA is a well-recognized complication after bone marrow transplantation with conventional conditioning. 8, 9 However, PRCA is a rare event. Since January 1995, 253 allogeneic stem cell transplantations with standard myeloablative conditioning with busulfan/cyclophosphamide or TBI-containing regimens have been performed at our institution. Although 71 patients received transplants from a major AB0-incompatible donor, only a single case of PRCA was observed. This isolated case was associated with acute parvovirus B19 infection.
In contrast, a retrospective analysis of the total of 23 consecutive patients transplanted according to the original FBM protocol revealed that two of five patients transplanted across a major AB0 barrier developed PRCA ( Table 1 ). The three patients who did not develop PRCA despite AB0 incompatibility had lower or negligible isoagglutinin titers, although a trend towards later recovery of erythropoieses may exist ( Table 1 ). The striking difference between reduced and conventional conditioning regimens may be attributable to less effective ablation of the host's humoral immunity when immunosuppression is based on fludarabine and CsA.
The eventual recovery of erythropoiesis in our patients may be explained by exhaustion of isoagglutinin-producing plasma cells due to scavenging of isoagglutinins through constant production of transplanted erythrocyte precursors. Alternatively, the eventual development of graft-versushost immunity may have eliminated these plasma cells.
Changing the immunosuppression to MMF may have also accelerated cessation of isoagglutinin production: MMF acts on lymphocytes of T and B cell lineage, whereas CsA inhibits only T cells. 10, 11 We conclude that with increasing use of fludarabinebased protocols for reduced-intensity conditioning, a higher incidence of PRCA should be expected in patients with anti-donor isoagglutinins in comparison to myeloablative regimens. Routine GVHD prophylaxis with MMF in addition to CsA deserves consideration for preventing post-transplant PRCA in patients at risk. In addition, preemptive measures such as in vivo depletion of plasma cells with monoclonal antibodies, plasmaphereses, immunoabsorption of isoagglutinin, or exhaustion of isoagglutinins by red cell transfusions with the donor's blood group could be useful to mitigate or prevent post-transplant PRCA.
